United States: FDA, State, And Local Governments Act To Modernize The Regulation Of Sunscreen Products In The United States

On February 26, 2019, FDA published its long-awaited proposed rule, Sunscreen Products for Over-the-Counter Human Use (Proposed Rule).1 The Proposed Rule is a step towards FDA's full compliance with the mandates of the 2014 Sunscreen Innovation Act (SIA)2 and builds on the stayed 1999 Sunscreen Final Monograph3 by proposing to, among other things, formally classify the safety and effectiveness of certain active ingredients and dosage forms, update sunscreen testing and recordkeeping requirements, and address new uses of sunscreens, including the sale of combination sunscreen-insect repellant products. FDA has proposed a 90-day comment period, and comments must be submitted on or before May 28, 2019.

In addition to updating testing and recordkeeping requirements, FDA proposes to:

  • classify zinc oxide and titanium dioxide as Category I (Generally Recognized as Safe and Effective – GRASE) sunscreen active ingredients, including certain products made with nanotechnology;
  • designate oil, lotion, cream, gel, butter, paste, ointment, stick, and spray sunscreen dosage forms as GRASE under the monograph (and the powder form potentially GRASE subject to FDA's receipt of additional safety and efficacy data regarding the dosage form);
  • designate all other dosage forms, including wipes, towelettes, body washes, and shampoos as "new drugs" that are ineligible for inclusion in the monograph;
  • establish new labeling and broad spectrum requirements (including a maximum SPF level of SPF 60+); and
  • classify combination insect repellant-sunscreen products as Category II (not GRASE).

Below, we provide an overview of the key provisions included in the Proposed Rule as well as other relevant state and city-level measures banning certain sunscreen active ingredients in Hawaii and Key West, FL. Given the increase in use of sunscreen ingredients in topical consumer products, including moisturizers and concealers, these developments are sure to impact any stakeholder in the OTC drug or personal care product industry.

I. Background

The Proposed Rule is FDA's most recent effort to modernize the regulation of sunscreen products in the US to account for increasing use of sunscreen in consumer products. The Proposed Rule builds on numerous Federal Register notices issued over the past decade4 and attempts to close the loop on the stayed 1999 Sunscreen Final Monograph by meeting the SIA's requirement to issue a final OTC sunscreen monograph by November 29, 2019. The SIA was passed in 2014 and amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to expedite the review of nonprescription sunscreen active ingredients that were not included in the stayed 1999 Sunscreen Final Monograph. While the SIA required issuance of this Proposed Rule (plus certain guidance documents), the sunscreen active ingredients submitted under the procedures established in FDA's Time and Extent Application (TEA) notice that are being considered under processes established by the SIA are not under consideration in the Proposed Rule.5

II. Overview of Proposed Sunscreen Rule

There are seven key takeaways in the Proposed Rule for stakeholders—(1) how FDA intends to classify 16 sunscreen active ingredients; (2) FDA's position on specific sunscreen dosage forms; (3) FDA's perspective on the use of nanomaterials and nanotechnology in sunscreen products; (4) FDA's proposed maximum labeled SPF values and broad spectrum requirements; (5) recommended labeling changes, including revisions to the products' statement of identity; (6) proposed modifications to sunscreen testing and recordkeeping requirements; and (7) FDA's proposal to classify combination insect-repellant sunscreen products as not GRASE.

A. Classification of Active Ingredients

Central to the Proposed Rule is FDA's safety assessment of sixteen sunscreen active ingredients that were originally included in the stayed 1999 Sunscreen Final Monograph. Following a review of publicly available data, including, but not limited to scientific literature, adverse event reports, submissions to the sunscreen monograph docket, FDA Advisory Committee Reports, and FDA and European Medicines Agency approval documents, FDA is proposing to classify the active ingredients as follows:

Category I (GRASE) Zinc Oxide, Titanium Dioxide
Category II (Not GRASE) Para-Aminobenzoic Acid (PABA), Trolamine Salicylate
Category III (Insufficient Data Available to Permit Final Classification) Avobenzone, Cinoxate, Dioxybenzone, Ensulizole, Homosalate, Meradimate, Octinoxate, Octisalate, Octocrylene, Oxybenzone, Padimate O, Sulisobenzone

Category I – GRASE

FDA proposes to classify zinc oxide and titanium dioxide as GRASE. For both active ingredients, FDA's determination is based, in no small part, on existing and substantial evidence that these mineral compounds largely do not penetrate the skin (even particles on the nanoscale (1-100 nanometers)), and to the extent that "de minimis" penetration occurs, do not cause adverse health effects.6  

Category II – Not GRASE

FDA proposes to classify para-aminobenzoic acid (PABA) and trolamine salicylate as not GRASE because the Agency has determined that the risks outweigh the benefits for the use of these active ingredients in sunscreen products. This determination should not affect the marketplace for sunscreen products or manufacturers in any measureable way because to FDA's knowledge, neither active ingredient is currently being marketed in sunscreen products in the United States.

Category III – Insufficient Data Available to Permit Final Classification

FDA proposes to classify cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, and avobenzone as active ingredients for which the public record lacks sufficient information to support a positive GRASE determination at this time. According to the Proposed Rule, "significant" data gaps exist for many of these active ingredients. For the active ingredients with significant data gaps (all except oxybenzone and avobenzone), FDA expects that data from clinical studies (e.g., human dermal safety studies and human absorption studies/maximal usage trial (MUsT)), nonclinical studies, and postmarketing safety information (including the evaluation of adverse events reported during the commercial marketing of sunscreens) will be necessary to support a positive GRASE finding.7 FDA expects that supporting a positive GRASE finding for oxybenzone and avobenzone will require fewer studies and data, and has set forth specific data requests regarding these two ingredients (e.g., providing carcinogenicity data and conducting MUsT studies).8 

Parties interested in submitting information regarding proposed Category III active ingredients  will need to work quickly—some of the recommended studies take anywhere from six months to two years to complete. Should manufacturers need additional time to provide safety or effectiveness data for a particular sunscreen active ingredient, FDA has expressed willingness to "consider requests to defer further rulemaking with respect to a specific sunscreen active ingredient to allow for the submission of new safety and/or effectiveness data to the record if such requests are submitted to the docket within the initial 90-day comment period."9

B. Sunscreen Dosage Forms

In 2011, FDA issued an Advance Notice of Proposed Rulemaking, requesting data and information about sunscreen dosage forms.10 In this document, FDA outlined the dosage forms that it believed were eligible for inclusion in a sunscreen monograph based on their history of marketing before the OTC Drug Review started in 1972, and dosage forms that would not be eligible for inclusion in such a monograph. FDA also solicited information about the safety and effectiveness of spray dosage forms. Following a review of the comments to the docket, plus additional information on the marketing history of sunscreen powder dosage forms, FDA has proposed to classify the following sunscreen dosage forms as Category I (GRASE): oil, lotion, cream, gel, butter, paste, ointment, stick, and spray. 

FDA has requested additional safety and efficacy data on the powder dosage form, though it is eligible for inclusion in the OTC sunscreen monograph. By contrast, FDA plans to consider all other dosage forms, including wipes, towelettes, body washes, and shampoos to be "new drugs" that are ineligible for inclusion in the OTC sunscreen monograph. FDA has taken the position that these dosage forms cannot be included in the monograph because, according to the proposed rule, FDA has no evidence that they were marketed prior to 1972.

While FDA has proposed that spray dosage forms are GRASE, due to the potential respiratory health risks from inhaling spray sunscreen and the potential flammability risk,11 FDA intends to impose formulation (particle size) limitations, labeling requirements, and particle size testing requirements on spray dosage forms in the final monograph. Regarding particle size, FDA proposes that 90% of the particles dispensed from a spray sunscreen must be at least 10 μm, while the other 10% must be 5 μm or greater.12 These same particle size limitations will also apply to powder dosage forms due to the risk of respiratory harm from inhalation. FDA also addressed concerns about the inhalation risk posed by the use of nanomaterials in spray sunscreens, but declined to propose conditions of use on nanomaterials in spray sunscreens because nanomaterials would not pass the 5 μm particle size requirement. The required particle size testing would be incorporated into the lot release testing that manufacturers perform as part of their current good manufacturing (cGMP) responsibilities under 21 CFR part 211.

C. Nanomaterials & Nanotechnology

In the Proposed Rule, FDA touches on the issue of sunscreens manufactured using nanotechnology or incorporating nanomaterials, particularly in reference to the proposed GRASE active ingredients and particle size requirements for spray sunscreens. As conveyed in the Proposed Rule, the Agency is not proposing to classify sunscreen products as Category I (GRASE) or Category II (not GRASE) based on the use of nanotechnology or nanomaterials.  Nor is FDA planning to establish regulatory definitions of nanotechnology, nanomaterials, or nanoscale in this context. It does, however, intend to apply the considerations described in FDA's June 2014 guidance for industry, Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology, to sunscreen products.13 Additionally, FDA has specifically solicited comments about the use of nanomaterials and sunscreens, including: "specific nanomaterials or types of nanomaterials that have been used or proposed for use in OTC sunscreen products; concerns about sunscreen product safety, effectiveness, or quality associated with the use of nanomaterials in OTC sunscreen products, with supporting data;" the need for certain specifications or limitations for the use of nanomaterials in OTC sunscreen; particular nanomaterials that should not be used in OTC sunscreen, plus supporting scientific data, and comments on FDA's posture towards the use of nanomaterials in OTC sunscreen.14

D. Proposed Maximum SPF, Labeling Ranges and Broad Spectrum Requirements

SPF Maximum & Labeling Ranges

FDA is proposing to raise the maximum labeled SPF value for sunscreen products to SPF 60+.  While FDA is proposing to permit sunscreen formulation up to SPF 80, manufacturers will not be able to convey that their products provide more SPF protection than 60+. The purpose of allowing a greater formulation value than labeled value is to account for the variability in SPF test results and to facilitate the development of products with improved UVA protection.15 Additionally, FDA proposes to require that sunscreens' labeled SPF values be based on a range of determined SPF values, as depicted in Table 5 below.

 

Broad Spectrum Requirement

FDA proposes to require that all sunscreens with a labeled SPF value of 15 and above provide broad spectrum protection, meaning protection from both UVA and UVB radiation. Sunscreens with a labeled SPF value below 15 need not provide broad spectrum protection. In fact, FDA is requesting comments on whether sunscreens with labeled SPF values from 2-14 should continue to be marketed. To qualify as broad spectrum, the sunscreen must "pass" the broad spectrum test, meaning that the product has a mean critical wavelength of 370nm or greater (a current requirement) and has a mean UVA I/UV ratio of 0.7 or higher (proposed requirement). This new test criteria should help ensure that sunscreens "have a more uniform amount of radiation protection across the UVA I, UVA II, and UVB ranges" and "eliminate the current potential for a product labeled as broad spectrum that has a higher SPF value to provide (unbeknownst to the consumer) poorer broad spectrum protection than a product labeled as broad spectrum with a lower SPF value."16

E. Labeling – Statement of Identity

Although FDA regulations currently require a statement of identity,17 the Proposed Rule sets forth specific requirements for sunscreen and sunscreen/skin protectant drug products. Per the technical requirements set forth in the Proposed Rule (including font size and placement requirements), the principal display panel (PDP) must display the statement of identity (SOI) as follows: the name of each sunscreen active ingredient listed in alphabetical order, followed by "Sunscreen" and the dosage form.18

F. Testing & Recordkeeping

FDA's regulations currently require final formulation testing to substantiate the labeled SPF values, water resistance statements, and broad spectrum statements.19 Citing concerns about current practices employed in final formulation testing, the Proposed Rule modifies the regulations governing testing to clarify the applicable requirements, improve study reliability, and to add protections for human subjects involved in the testing. Notably, the Proposed Rule clarifies that FDA's regulations pertaining to informed consent (21 CFR part 50) and IRB approval of research (21 CFR part 56) apply to clinical final formulation testing set forth in proposed 21 CFR 201.327(i).20 Additionally, the Proposed Rule imposes new recordkeeping requirements for final formulation testing (which FDA understands to be a manufacturing activity subject to cGMP requirements) that are aligned with requirements for other types of manufacturing subject to cGMPs.21 The Proposed Rule outlines who should retain records, the types of records that must be kept, and FDA's right to access testing records.22 It is particularly important for regulated industry to pay attention to these requirements because the Proposed Rule imposes penalties of misbranding for failure to comply with any of the provisions in proposed 21 CFR 201.327 (including failure to conduct final formulation testing in a registered establishment), and FDA may find that a product is adulterated for failure to comply with cGMPs or recordkeeping requirements in proposed 21 CFR 201.327.23

To clarify the responsibility for complying with the final formulation testing and recordkeeping requirements, the Proposed Rule creates a new term – "Responsible Person" – defined as the "manufacturer, packer, or distributor whose name appears on the labeling of a sunscreen product covered by this section."24 The Responsible Person's obligations are modeled after the regulatory obligations applicable to an investigational new drug (IND) application sponsor, and incorporate certain investigator responsibilities, yet are tailored to the specific sunscreen clinical and nonclinical formulation testing. For example, the Responsible Person must "select appropriately qualified personnel to conduct testing, ensure compliance with the requirements for IRB review and obtaining informed consent, and monitor the compliance of personnel with investigators' statements[,]" as well as comply with the new recordkeeping requirements.25 A Responsible Person may transfer all of its responsibilities under part 327 to another entity (e.g., a contract research organization and/or testing laboratory), except for recordkeeping requirements. 

G. Combination Insect-Repellent and Sunscreen Products

Products containing sunscreens and insect repellants are subject to regulation by FDA under the FD&C Act, and the Environmental Protection Agency as pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). FDA has a number of concerns about these combination products, including how the interactions between sunscreen active ingredients and insect repellants may affect the safety and efficacy of the combined product. Following a review of the scientific literature, publicly-available EPA regulatory documents, and comments submitted in response to a "2007 Call for Data", FDA proposes to classify these products as Category II (not GRASE), and misbranded because "conflicting labeling requirements for their sunscreen and insect repellent components cannot be reconciled to create labeling that will sufficiently ensure safe and effective use of the sunscreen, as well as adequate directions for use as a sunscreen . . ."26

III. Request for Comments & Compliance Deadline

As noted, FDA has proposed a 90-day comment period, and comments must be submitted on or before May 28, 2019. FDA may consider requests to defer further rulemaking for a specific sunscreen active ingredient to allow for the submission of additional safety and/or efficacy data if such requests or comments are received within this 90-day comment period. If a sunscreen active ingredient is deferred, FDA expects that products containing that active ingredient can stay on the market while data is being gathered and studies are ongoing.27 Commissioner Gottlieb recently tweeted that the Agency "plan[s] to finalize the sunscreen proposed rule for the non-deferred ingredients and the other aspects of the rule. Once we receive data on a deferred ingredient and have a chance to consider such data, we intend to issue a final rule with our determination for that ingredient."28

FDA anticipates requiring full compliance with the final regulations one year after the effective date of the final rule, which could be as early as November 26, 2020. Note that the Agency does not intend to require full compliance with the final regulations for products introduced or delivered into interstate commerce prior to the compliance date (e.g., products in retail stores).

IV. State and City-Level Measures Banning Sunscreen Active Ingredients

Aside from measures at the federal level to address sunscreen active ingredient safety for use in humans, states are implementing (or considering) measures to prohibit certain sunscreen active ingredients due to the risk of environmental harm. For example, Hawaii's legislature determined that oxybenzone and octinoxate were significantly harmful to Hawaii's marine environment and ecosystems, and were damaging coral reefs and pursued legislation to mitigate this problem.29 Subsequently, on July 3, 2018, Hawaii's governor signed SB 2571, Act 104 into law, prohibiting the sale, offer for sale, or distribution for sale in Hawaii of any SPF sunscreen products contain oxybenzone and octinoxate starting on January 1, 2021.30 California's legislature attempted to follow in Hawaii's footsteps, introducing Assembly Bill 60, a bill to prohibit the sale of sunscreens containing octinoxate or oxybenzone without a prescription.31 Likewise, the city of Key West, Florida recently voted to ban the sale of sunscreens containing oxybenzone and octinoxate starting in January 2021, citing harm to coral reefs.32

*          *          *

Our team has carefully reviewed the Proposed Rule and the related state and local developments impacting the sale of products that contain sunscreen ingredients. We will continue to monitor developments in this area.

Footnotes

1 Sunscreen Products for Over-the-Counter Human Use, 84 Fed. Reg. 6204, Feb. 26, 2019.

2 21 USC § 360fff-5.  The SIA requires FDA to issue a final OTC sunscreen monograph within five years of enactment of the SIA (by Nov. 29, 2019).

3  Sunscreen Drug Products For Over-The-Counter Human Use; Final Monograph, 98 Fed. Reg. 27666, May 21, 1999 (stayed on Dec. 31, 2001, 66 Fed. Reg. 67485).

4 Sunscreen Drug Product for Over-the-Counter Human Use; Request for Data and Information Regarding Dosage Forms, 76 Fed. Reg. 35669 (June 17, 2011).

5 The status and next steps for these active ingredients is available  here. Note that the Proposed Rule does not address the safety of or establish a pathway for considering sunscreen active ingredients that are approved in other countries.

6 Note, FDA is not planning to impose any conditions on the use of nanomaterial forms of these active ingredients.  84 Fed. Reg. at 6216.

7 FDA noted that data from MUsT studies "should be properly validated according to good laboratory practices (21 CFR part 58). 84 Fed. Reg. at 6214.

8 84 Fed. Reg. at 6224, 6228.

9 84 Fed. Reg. at 6249.

10 Sunscreen Drug Product for Over-the-Counter Human Use; Request for Data and Information Regarding Dosage Forms, 76 Fed. Reg. 35669 (June 17, 2011).

11  The risk is posed by, for example, exposure to an open flame before the spray sunscreen has dried.

12 Based on the particle size data submitted to the 2011 ANPR docket, FDA believes that this limitation would not "unduly burden" sunscreen manufacturers.

13 84 Fed. Reg. at 6215, citing FDA Guidance for Industry, Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology, June 2014. Specifically, FDA intends to apply these two points from the guidance in particular: "(1) Whether a material or end product is engineered to have at least one external dimension, or an internal or surface structure, in the nanoscale range (approximately 1 nm to 100 nm); (2) Whether a material or end-product is engineered to exhibit properties or phenomena, including physical or chemical properties or biological effects, that are attributable to its dimension(s), even if these dimensions fall outside the nanoscale range, up to 1 micrometer (mm) (1,000 nm)."

14 84 Fed. Reg. at 6216.

15 84 Fed. Reg. at 6237.

16 84 Fed. Reg. at 6235.

17 See 21 CFR 201.66.

18 84 Fed. Reg. at 6239.

19 21 CFR 201.327(i), (j).

20  84 Fed. Reg. at 6241.

21 84 Fed. Reg. at 6243.

22 84 Fed. Reg. at 6242-6243, 6271.

23 84 Fed. Reg. at 6242, 6264, 6271.

24 84 Fed. Reg. at 6241. The purpose of creating this definition is to help FDA assess compliance with section 327 because "it creates a chain of responsibility that is immediately apparent from the product's labeling.

25 84 Fed. Reg. at 6241-6243.

26 84 Fed. Reg. at 6245.

27  Tweets of Scott Gottlieb, M.D., Mar. 2, 2019, 10:54 a.m.

28 Tweets of Scott Gottlieb, M.D., Mar. 2, 2019, 10:55 a.m.

29 Hawaii SB 2571, Act 104.

30 Press Release, Governor David Ige Signs Bill Making Hawaii First in the World to Ban Certain Sunscreens, Jul. 3, 2018; Hawaii SB 2571, Act 104.

31 California Legislature, Assembly Bill No. 60. Assembly Bill 60 was recently amended into an unrelated bill; thus, California likely will not seek to address this issue on the statewide level this year.  Further action on this legislation may be pursued in 2020, depending to some extent on FDA's determination of active ingredient safety.

32 Washington Post, "We Have One Reef": Key West Bans Popular Sunscreens to Help Keep Coral Alive, Feb. 6, 2019.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
 
Email Address
Company Name
Password
Confirm Password
Country
Position
Industry
Mondaq Newsalert
Select Topics
Select Regions
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions